CVS Health Corporation $CVS Position Boosted by Elevated Capital Advisors LLC

Key Points

• Elevated Capital Advisors dramatically increased its CVS Health stake in Q1, boosting holdings by 6,039.9% to 10,008 shares worth about $719,000.
• Insider selling has been heavy, including large sales by EVP Tilak Mandadi and Director Larry Robbins; insiders sold 3.44 million shares worth about $323.7 million over the last 90 days.
• CVS remains well covered by analysts and institutions, with 80.66% of shares held by institutional investors and a consensus rating of “Moderate Buy,” while the company also reported better-than-expected quarterly earnings and raised its FY2026 EPS guidance.

Elevated Capital Advisors LLC increased its position in CVS Health Corporation (NYSE:CVS - Free Report) by 6,039.9% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 10,008 shares of the pharmacy operator's stock after purchasing an additional 9,845 shares during the period. Elevated Capital Advisors LLC's holdings in CVS Health were worth $719,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Norges Bank acquired a new position in shares of CVS Health in the 4th quarter worth approximately $1,666,265,000. Wellington Management Group LLP increased its holdings in shares of CVS Health by 193.2% in the 4th quarter. Wellington Management Group LLP now owns 18,564,392 shares of the pharmacy operator's stock valued at $1,473,270,000 after acquiring an additional 12,233,675 shares during the last quarter. Amundi raised its position in shares of CVS Health by 95.3% during the 3rd quarter. Amundi now owns 7,453,980 shares of the pharmacy operator's stock valued at $572,665,000 after acquiring an additional 3,637,943 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its stake in CVS Health by 70.5% during the third quarter. Arrowstreet Capital Limited Partnership now owns 5,294,134 shares of the pharmacy operator's stock worth $399,125,000 after purchasing an additional 2,188,307 shares during the last quarter. Finally, Hamlin Capital Management LLC acquired a new position in CVS Health in the fourth quarter worth $160,844,000. Institutional investors and hedge funds own 80.66% of the company's stock.

Insider Activity at CVS Health

In related news, EVP Tilak Mandadi sold 69,551 shares of the stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $89.58, for a total value of $6,230,378.58. Following the completion of the transaction, the executive vice president directly owned 10,133 shares of the company's stock, valued at $907,714.14. This represents a 87.28% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Larry Robbins sold 370,462 shares of the firm's stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $93.45, for a total value of $34,619,673.90. Following the completion of the sale, the director owned 4,824,799 shares in the company, valued at approximately $450,877,466.55. This represents a 7.13% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 3,441,551 shares of company stock worth $323,703,977 in the last 90 days. 0.85% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several research firms have weighed in on CVS. Morgan Stanley boosted their target price on shares of CVS Health from $106.00 to $111.00 and gave the company an "overweight" rating in a research note on Thursday, June 4th. Royal Bank Of Canada raised their price target on shares of CVS Health from $107.00 to $113.00 and gave the stock an "outperform" rating in a research report on Thursday. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of CVS Health from $88.00 to $92.00 and gave the company a "buy" rating in a research report on Thursday, May 7th. Mizuho increased their price objective on shares of CVS Health from $110.00 to $115.00 and gave the stock an "outperform" rating in a research note on Monday, June 8th. Finally, Piper Sandler reissued an "overweight" rating and issued a $113.00 target price on shares of CVS Health in a report on Monday, June 1st. Twenty-one investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $102.84.

CVS Health News Summary

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS Health declared a quarterly dividend of $0.665 per share, reinforcing its shareholder-return policy and signaling management confidence in cash generation. CVS Health declares quarterly dividend
• Positive Sentiment: Coverage around CVS highlighted the company as a likely beneficiary of managed-care consolidation, with commentary that Aetna is handling medical costs and that CVS is well positioned as Walgreens weakens. Cramer’s Stop Trading: CVS Health
• Neutral Sentiment: A CVS executive, Ali Keshavarz, was appointed to the board of Choice Hotels; this is notable for the executive’s profile but does not appear to have a direct operational impact on CVS. Choice Hotels (CHH) Appoints CVS Data Chief To Board As Index Changes Hit
• Negative Sentiment: CVS and Omnicare agreed to a $440 million settlement with the U.S. Department of Justice to resolve improper billing allegations, which creates a large one-time legal cost and keeps regulatory pressure on the company. CVS, Omnicare ink $440M deal with DoJ to resolve improper billing case
• Negative Sentiment: CVS also settled a separate $36.5 million case tied to false Medicaid insulin claims, adding to the legal overhang and reinforcing concerns about compliance risks. CVS settles for $36.5M over false Medicaid insulin claims, Minnesota recovers $400K

CVS Health Stock Performance

CVS stock opened at $104.15 on Friday. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.66 and a current ratio of 0.87. The stock has a market capitalization of $132.88 billion, a price-to-earnings ratio of 45.88, a PEG ratio of 1.01 and a beta of 0.61. CVS Health Corporation has a 1 year low of $58.50 and a 1 year high of $106.15. The stock's fifty day moving average is $96.91 and its two-hundred day moving average is $84.17.

CVS Health (NYSE:CVS - Get Free Report) last released its quarterly earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 EPS for the quarter, topping the consensus estimate of $2.21 by $0.36. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The business had revenue of $100.43 billion during the quarter, compared to analyst estimates of $94.99 billion. During the same quarter in the prior year, the firm earned $2.25 earnings per share. The company's quarterly revenue was up 6.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. On average, research analysts predict that CVS Health Corporation will post 7.44 EPS for the current year.

CVS Health Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, August 3rd. Shareholders of record on Thursday, July 23rd will be given a $0.665 dividend. The ex-dividend date is Thursday, July 23rd. This represents a $2.66 annualized dividend and a yield of 2.6%. CVS Health's dividend payout ratio is 117.18%.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corporation (NYSE:CVS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.